miR‑19 in blood plasma reflects lung cancer occurrence but is not specifically associated with radon exposure

Bulgakova,Olga; Zhabayeva,Dinara; Kussainova,Assiya; Pulliero,Alessandra; Izzotti,Alberto; Bersimbaev,Rakhmetkazhi

doi:10.3892/ol.2018.8392

miR‑19 in blood plasma reflects lung cancer occurrence but is not specifically associated with radon exposure

Authors:
- Olga Bulgakova
- Dinara Zhabayeva
- Assiya Kussainova
- Alessandra Pulliero
- Alberto Izzotti
- Rakhmetkazhi Bersimbaev
View Affiliations

Affiliations: Department of General Biology and Genomics, Institute of Cell Biology and Biotechnology, L.N. Gumilyov Eurasian National University, Astana, Akmola 010008, Kazakhstan, Department of Health Sciences, University of Genoa, Genoa, I‑16132 Liguria, Italy
Published online on: March 30, 2018 https://doi.org/10.3892/ol.2018.8392
Pages: 8816-8824

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radon is one of the most powerful carcinogens, particularly in terms of lung cancer onset and development. miRNAs may be considered not only as markers of the ongoing tumorigenesis but also as a hallmark of exposure to radiation, including radon and its progeny. Therefore, the purpose of the present study was to estimate the value of plasma miR‑19b‑3p level as the prospective marker of the response to radon exposure in lung cancer pathogenesis. A total of 136 subjects were examined, including 49 radon‑exposed patients with lung cancer, 37 patients with lung cancer without radon exposure and 50 age/sex matched healthy controls. Total RNA from blood samples was extracted and used to detect miR‑19b‑3p expression via reverse transcription quantitative‑polymerase chain reaction. The 2‑ΔΔCq method was used to quantify the amount of relative miRNA. The plasma level of p53 protein was determined using a Human p53 ELISA kit. Plasma miR‑19b‑3p level was significantly higher in the patients with lung cancer groups, compared with the healthy control group (P<0.0001). No other statistically significant differences were determined in the expression level of plasma miR‑19b‑3p between patients diagnosed with lung cancer exposed to radon and not exposed to radon. The expression level of free circulating miR‑19b‑3p was higher in the group of non‑smoking patients with lung cancer, compared with smokers with lung cancer. The miR‑19b‑3p was 1.4‑fold higher in non‑smokers than in smokers (P<0.05). No association between plasma levels of p53 protein and miR‑19b‑3p freely circulating in patients with lung cancer was observed. No other statistically significant differences were determined in the plasma p53 protein level between patients diagnosed with lung cancer exposed and not exposed to radon. These results indicated that detection of miR‑19b‑3p levels in plasma potentially could be exploited as a noninvasive method for the lung cancer diagnostics. However, this miRNA is not suitable as the precise marker for radon impact.

View Figures

View References

1	Amin J, Sharif M and Yasmin M: Segmentation and classification of lung cancer: A review. Immunol Endo Metab Age Med Chem. 16:82–99. 2016. View Article : Google Scholar
2	Zeeb H and Shannon F: WHO handbook on indoor radon: A public health perspectiveWorld Health Organization. Zeeb H and Shannon F: World Health Organization; Geneva: pp. 3–21. 2009
3	Ahn YS and Jeong KS: Epidemiologic characteristics of compensated occupational lung cancers among Korean workers. J Korean Med Sci. 29:1473–1481. 2014. View Article : Google Scholar : PubMed/NCBI
4	Izzotti A, Carozzo S, Pulliero A, Zhabayeva D, Ravetti JL and Bersimbaev R: Extracellular MicroRNA in liquid biopsy: Applicability in cancer diagnosis and prevention. Am J Cancer Res. 6:1461–1493. 2016.PubMed/NCBI
5	Anglicheau D, Muthukumar T and Suthanthiran M: MicroRNAs: Small RNAs with big effects. Transplantation. 90:105–112. 2010. View Article : Google Scholar : PubMed/NCBI
6	Nishida N, Arizumi T, Hagiwara S, Ida H, Sakurai T and Kudo M: MicroRNAs for the prediction of early response to Sorafenib treatment in human hepatocellular carcinoma. Liver Cancer. 6:113–125. 2017. View Article : Google Scholar : PubMed/NCBI
7	Nassar FJ, Nasr R and Talhouk R: MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 172:34–49. 2017. View Article : Google Scholar : PubMed/NCBI
8	Hemmatzadeh M, Mohammadi H, Karimi M, Musavishenas MH and Baradaran B: Differential role of microRNAs in the pathogenesis and treatment of esophageal cancer. Biomed Pharmacother. 82:509–519. 2016. View Article : Google Scholar : PubMed/NCBI
9	Kumar B and Lupold SE: MicroRNA expression and function in prostate cancer: A review of current knowledge and opportunities for discovery. Asian J Androl. 18:559–567. 2016. View Article : Google Scholar : PubMed/NCBI
10	Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N and Nakamura Y: Gene expression profiles of small-cell lung cancers: Molecular signatures of lung cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
11	Wu C, Cao Y, He Z, He J, Hu C, Duan H and Jiang J: Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med. 232:85–95. 2014. View Article : Google Scholar : PubMed/NCBI
12	Li J, Yang S, Yan W, Yang J, Qin YJ, Lin XL, Xie RY, Wang SC, Jin W, Gao F, et al: MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Lab Invest. 95:1056–1070. 2015. View Article : Google Scholar : PubMed/NCBI
13	Lin Q, Chen T, Lin Q, Lin G, Lin J, Chen G and Guo L: Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol. 107:767–771. 2013. View Article : Google Scholar : PubMed/NCBI
14	Chaudhry MA: Radiation-induced microRNA: Discovery, functional analysis, and cancer radiotherapy. J Cell Biochem. 115:436–449. 2014. View Article : Google Scholar : PubMed/NCBI
15	Cui FM, Li JX, Chen Q, Du HB, Zhang SY, Nie JH, Cao JP, Zhou PK, Hei TK and Tong J: Radon-induced alterations in micro-RNA expression profiles in transformed BEAS2B cells. J Toxicol Environ Health A. 76:107–119. 2013. View Article : Google Scholar : PubMed/NCBI
16	Yngveson A, Williams C, Hjerpe A, Lundeberg J, Söderkvist P and Pershagen G: p53 mutations in lung cancer associated with residential radon exposure. Cancer Epidemiol Biomarkers Prev. 8:433–438. 1999.PubMed/NCBI
17	Deben C, Deschoolmeester V, Lardon F, Rolfo C and Pauwels P: TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. Crit Rev Oncol Hematol. 99:63–73. 2016. View Article : Google Scholar : PubMed/NCBI
18	Vähäkangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP and Harris CC: Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 339:576–580. 1992. View Article : Google Scholar : PubMed/NCBI
19	Taylor JU, Watson MA, Devereux TR, Michels RY, Saccomanno G and Anderson M: p53 mutation hotspot in radon-associated lung cancer. Lancet. 343:86–87. 1994. View Article : Google Scholar : PubMed/NCBI
20	Lo YM, Darby S, Noakes L, Whitley E, Silcocks PB, Fleming KA and Bell JI: Screening for codon 249 p53 mutation in lung cancer associated with domestic radon exposure. Lancet. 345:601995. View Article : Google Scholar : PubMed/NCBI
21	Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al: p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
22	Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, et al: Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 6:458–472. 2012. View Article : Google Scholar : PubMed/NCBI
23	Liao JM, Cao B, Zhou X and Lu H: New insights into p53 functions through its target microRNAs. J Mol Cell Biol. 6:206–213. 2014. View Article : Google Scholar : PubMed/NCBI
24	Fan Y, Yin S, Hao Y, Yang J, Zhang H, Sun C, Ma M, Chang Q and Xi JJ: mir-19b promotes tumor growth and metastasis via targeting TP53. RNA. 20:765–772. 2014. View Article : Google Scholar : PubMed/NCBI
25	Zhang N, Wei X and Xu L: miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett. 587:2346–2351. 2013. View Article : Google Scholar : PubMed/NCBI
26	Talekar M, Trivedi M, Shah P, Ouyang Q, Oka A, Gandham S and Amiji MM: Combination wt-p53 and MicroRNA-125b transfection in a genetically engineered lung cancer model using dual CD44/EGFR-targeting nanoparticles. Mol Ther. 24:759–769. 2016. View Article : Google Scholar : PubMed/NCBI
27	Sobin LH: TNM: Principles, history, and relation to other prognostic factors. Cancer. 91 8 Suppl:S1589–S1592. 2001. View Article : Google Scholar
28	Izzotti A, Calin GA, Steele VE, Croce CM and De Flora S: Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light. FASEB J. 23:3243–3250. 2009. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Quarto M, Pugliese M, La Verde G, Loffredo F and Roca V: Radon exposure assessment and relative effective dose estimation to inhabitants of puglia region, South Italy. Int J Environ Res Public Health. 12:14948–14957. 2015. View Article : Google Scholar : PubMed/NCBI
31	Naeini MM and Ardekani AM: Noncoding RNAs and cancer. Avicenna J Med Biotechnol. 1:55–70. 2009.PubMed/NCBI
32	Jansson MD and Lund AH: MicroRNA and cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
33	Morey C and Avner P: Employment opportunities for non-coding RNAs. FEBS Lett. 567:27–34. 2004. View Article : Google Scholar : PubMed/NCBI
34	Rasool M, Malik A, Zahid S, Ashraf MAB, Qazi MH, Asif M, Zaheer A, Arshad M, Raza A and Jamal MS: Non-coding RNAs in cancer diagnosis and therapy. Non-coding RNA Res. 1:69–76. 2016. View Article : Google Scholar
35	Inamura K: Major tumor suppressor and oncogenic non-coding RNAs: Clinical relevance in lung cancer. Cells. 6:pii: E12. 2017. View Article : Google Scholar : PubMed/NCBI
36	Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V and Bansa P: MicroRNA therapeutics: Discovering novel targets and developing specific therapy. Perspect Clin Res. 7:68–74. 2016. View Article : Google Scholar : PubMed/NCBI
37	Inamura K: Diagnostic and therapeutic potential of MicroRNAs in lung cancer. Cancers (Basel). 9:pii: E49. 2017. View Article : Google Scholar
38	Inamura K and Ishikawa Y: MicroRNA in lung cancer: Novel biomarkers and potential tools for treatment. J Clin Med. 5:pii: E36. 2016. View Article : Google Scholar : PubMed/NCBI
39	Ottman R, Levy J, Grizzle WE and Chakrabarti R: The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer. Oncotarget. 7:73739–73753. 2016. View Article : Google Scholar : PubMed/NCBI
40	Wu Q, Yang Z, Wang F, Hu S, Yang L, Shi Y and Fan D: MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. J Cell Sci. 126:4220–4229. 2013. View Article : Google Scholar : PubMed/NCBI
41	Li J, Yang S, Yan W, Yang J, Qin YJ, Lin XL, Xie RY, Wang SC, Jin W, Gao F, et al: MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Lab Invest. 95:1056–1070. 2015. View Article : Google Scholar : PubMed/NCBI
42	Molinari C, Salvi S, Foca F, Teodorani N, Saragoni L, Puccetti M, Passardi A, Tamberi S, Avanzolini A, Lucci E and Calistri D: miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 9:2735–2742. 2016.PubMed/NCBI
43	Zhou X, Wen W, Shan X, Zhu W, Xu J, Guo R, Cheng W, Wang F, Qi LW, Chen Y, et al: A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis. Oncotarget. 8:6513–6525. 2017.PubMed/NCBI
44	Hu W, Jin P, Ding C and Liu W: miR-19a/b modulates lung cancer cells metastasis through suppression of MXD1 expression. Oncol Lett. 12:1901–1905. 2016. View Article : Google Scholar : PubMed/NCBI
45	Stayner L, Bena J, Sasco AJ, Smith R, Steenland K, Kreuzer M and Straif K: Lung cancer risk and workplace exposure to environmental tobacco smoke. Am J Public Health. 97:545–551. 2007. View Article : Google Scholar : PubMed/NCBI
46	Field RW and Withers BL: Occupational and environmental causes of lung cancer. Clin Chest Med. 33:681–703. 2012. View Article : Google Scholar : PubMed/NCBI
47	Inamura K, Ninomiya H, Nomura K, Tsuchiya E, Satoh Y, Okumura S, Nakagawa K, Takata A, Kohyama N and Ishikawa Y: Combined effects of asbestos and cigarette smoke on the development of lung adenocarcinoma: Different carcinogens may cause different genomic changes. Oncol Rep. 32:475–482. 2014. View Article : Google Scholar : PubMed/NCBI
48	Bersimbaev RI and Bulgakova O: The health effects of radon and uranium on the population of Kazakhstan. Genes Environ. 37:182015. View Article : Google Scholar : PubMed/NCBI
49	National Research Council: (US) Committee on health risks of exposure to radon (BEIR VI)Health effects of exposure to radon: BEIR VI. Washington (DC): National academies press (US); 1999, https://www.ncbi.nlm.nih.gov/books/NBK233262/
50	Shi B, Gao H, Zhang T and Cui Q: Analysis of plasma microRNA expression profiles revealed different cancer susceptibility in healthy young adult smokers and middle-aged smokers. Oncotarget. 7:21676–21685. 2016.PubMed/NCBI
51	Gross TJ, Powers LS, Boudreau RL, Brink B, Reisetter A, Goel K, Gerke AK, Hassan IH and Monick MM: A microRNA processing defect in smokers' macrophages is linked to SUMOylation of the endonuclease DICER. J Biol Chem. 289:12823–12834. 2014. View Article : Google Scholar : PubMed/NCBI
52	Izzotti A, Balansky R, Ganchev G, Iltcheva M, Longobardi M, Pulliero A, Geretto M, Micale RT, La Maestra S, Miller MS, et al: Blood and lung microRNAs as biomarkers of pulmonary tumorigenesis in cigarette smoke-exposed mice. Oncotarget. 7:84758–84774. 2016. View Article : Google Scholar : PubMed/NCBI
53	Izzotti A and Pulliero A: The effects of environmental chemical carcinogens on the microRNA machinery. Int J Hyg Environ Health. 217:601–627. 2014. View Article : Google Scholar : PubMed/NCBI
54	Balansky R, Izzotti A, D'Agostini F, Longobardi M, Micale R, La Maestra S, Camoirano A, Ganchev G, Iltcheva M, Steele VE and De Flora S: Assay of lapatinib in murine models of cigarette smoke carcinogenesis. Carcinogenesis. 35:2300–2307. 2014. View Article : Google Scholar : PubMed/NCBI
55	Jarry J, Schadendorf D, Greenwood C, Spatz A and van Kempen LC: The validity of circulating microRNAs in oncology: Five years of challenges and contradictions. Mol Oncol. 8:819–829. 2014. View Article : Google Scholar : PubMed/NCBI
56	Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, et al: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
57	Mendell J: miRiad roles for the miR-17-92 cluster in development and disease. Cell. 133:217–222. 2008. View Article : Google Scholar : PubMed/NCBI
58	Lu Y, Thomson JM, Wong HY, Hammond SM and Hogan BL: Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol. 310:442–453. 2007. View Article : Google Scholar : PubMed/NCBI
59	Lee HJ, Guo HY, Lee SK, Jeon BH, Jun CD, Lee SK, Park MH and Kim EC: Effects of nicotine on proliferation, cell cycle, and differentiation in immortalized and malignant oral keratinocytes. J Oral Pathol Med. 34:436–443. 2005. View Article : Google Scholar : PubMed/NCBI
60	Ng TK, Huang L, Cao D, Yip YW, Tsang WM, Yam GH, Pang CP and Cheung HS: Cigarette smoking hinders human periodontal ligament-derived stem cell proliferation, migration, and differentiation potentials. Sci Rep. 5:78282015. View Article : Google Scholar : PubMed/NCBI
61	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
62	Fischer M: Census and evaluation of p53 target genes. Oncogene. 36:3943–3956. 2017. View Article : Google Scholar : PubMed/NCBI
63	Pflaum J, Schlosser S and Müller M: p53 family and cellular stress responses in cancer. Front Oncol. 4:2852014. View Article : Google Scholar : PubMed/NCBI
64	Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T and Yasumoto K: Expression of the p53 family in lung cancer. Anticancer Res. 26:1785–1790. 2006.PubMed/NCBI
65	Hasbek Z, Doğan ÖT, Sarı İ, Yücel B, Şeker MM, Turgut B, Berk S and Siliğ Y: The diagnostic value of the correlation between serum Anti-p53 antibody and positron emission tomography parameters in lung cancer. Mol Imaging Radionucl Ther. 25:107–113. 2016. View Article : Google Scholar : PubMed/NCBI
66	Ruano-Ravina A, Pérez-Becerra R, Fraga M, Kelsey KT and Barros-Dios JM: Analysis of the relationship between p53 immunohistochemical expression and risk factors for lung cancer, with special emphasis on residential radon exposure. Ann Oncol. 19:109–114. 2008. View Article : Google Scholar : PubMed/NCBI
67	Schneider J, Presek P, Braun A and Woitowitz H: Serum levels of pantropic p53 protein and EGF-receptor, and detection of anti-p53 antibodies in former uranium miners (SDAG Wismut). Am J Ind Med. 36:602–609. 1999. View Article : Google Scholar : PubMed/NCBI